Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of empagliflozin + metformin fixed-dose combination tablets under fed conditions in healthy Thai volunteers
TCTR20260929007Phase 1Not yet recruiting
- Sponsor
- T.O. Chemicals
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of empagliflozin and metformin (2 arms), sponsored by T.O. Chemicals. Primary endpoints: Maximum empagliflozin plasma concentration, Maximum metformin plasma concentration and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
empagliflozinmetformin
Beyond the preview
Go deeper on TCTR20260929007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260929007.